Core Viewpoint - The company, Shanhe Pharmaceutical (300452), announced the nomination of Ms. Wu Changhong as a candidate for the sixth board of directors as a non-independent director [1] Summary by Relevant Sections - **Company Announcement** - The board of directors of Shanhe Pharmaceutical has approved the nomination of Ms. Wu Changhong for the position of non-independent director [1]

Core Points - The company reported a revenue of 697 million yuan for the first three quarters of 2025, representing a year-on-year growth of 8.09% [1] - The net profit attributable to shareholders for the same period was 133 million yuan, with a year-on-year increase of 8.28% [1] - In the third quarter alone, the company achieved a revenue of 226 million yuan, marking a year-on-year growth of 16.06% [1] - The net profit for the third quarter was approximately 39.53 million yuan, showing a significant year-on-year increase of 46.99% [1]

Core Insights - The company reported a revenue of 225,663,160.30 yuan for the third quarter of 2025, representing a year-on-year growth of 16.06% [2] - The net profit attributable to shareholders of the listed company was 39,528,758.33 yuan, showing a significant year-on-year increase of 46.99% [2] Financial Performance - Revenue for Q3 2025: 225.66 million yuan, up 16.06% year-on-year [2] - Net profit for Q3 2025: 39.53 million yuan, up 46.99% year-on-year [2]

Group 1 - Yonghe Co., Ltd. reported a net profit of 469 million yuan for the first three quarters, a year-on-year increase of 220.39% [1] - Jinli Permanent Magnet achieved a net profit of 515 million yuan, reflecting a year-on-year growth of 161.81% [1][2] - Sanhe Pharmaceutical Auxiliary's net profit increased by 8.28% year-on-year, reaching 133 million yuan [2] Group 2 - Jiahuan Technology experienced a net profit decline of 26.53%, totaling 55.35 million yuan [3] - Wuchan Huaneng reported a net profit decrease of 15.10%, amounting to 453 million yuan [3] - Chuan Investment Energy's net profit fell by 4.54%, totaling 4.22 billion yuan [4][5] Group 3 - Dayang Bio's net profit grew by 56.12%, reaching 80 million yuan [5] - Weili Medical reported a net profit increase of 14.94%, totaling 192 million yuan [6] - People's Tongtai's net profit decreased by 45.69%, amounting to 112 million yuan [7] Group 4 - Jiuhuan Bio received a medical device registration certificate for its NT-proBNP test kit [8] - Jincheng Pharmaceutical's subsidiary obtained a drug registration certificate for a specific injection [9] - Guangdian Yuntong's subsidiary acquired a money service operator license in Hong Kong [10] Group 5 - Dash Intelligent won a bid for a project worth 96 million yuan related to the Shijiazhuang subway [10] - Alloy Investment's net profit increased by 124.87%, reaching 7.26 million yuan [11] - Kaile Co., Ltd. reported a net profit growth of 159.14%, totaling 21.63 million yuan [12] Group 6 - Chuanjinno's net profit surged by 175.61%, reaching 304 million yuan [14] - Rijiu Optoelectronics reported a net profit increase of 36.54%, totaling 76.91 million yuan [15] - Dazhu CNC's net profit grew by 142.19%, amounting to 492 million yuan [15] Group 7 - Nairui Radar expects a net profit increase of 181% for the first three quarters [17] - Suzhou Tianmai successfully acquired land use rights for a new manufacturing project [19] - Aokai Pharmaceutical announced clinical research data for its innovative drug at a major conference [21][22] Group 8 - Jilin Aodong's subsidiary passed the consistency evaluation for a specific injection [24] - Qinxin Environment announced the resignation of a board member [25] - *ST Baoying is planning a change in control, leading to a stock suspension [26] Group 9 - Jianlang Hardware's director plans to reduce holdings by up to 500,000 shares [27] - Taihe Technology's director intends to reduce holdings by up to 606,000 shares [29] - Zhongyuan Securities announced a cash dividend of 0.008 yuan per share [31] Group 10 - Beijing-Shanghai High-Speed Railway plans to distribute a cash dividend of 0.0385 yuan per share [32] - Zhuhai Guanyu expects a net profit increase of 36.88%-55.54% for the first three quarters [34] - Shenglong Co., Ltd. reported a net loss of 72.95 million yuan for the first three quarters [36] Group 11 - Shuangyuan Technology plans to distribute a cash dividend of 0.125 yuan per share [38] - Shaanxi Guotou A reported a net profit increase of 6.6%, totaling 996 million yuan [40] - Sunshine Nuohua intends to invest 15 million yuan in a biotech company [41] Group 12 - Yangjie Technology's net profit increased by 45.51%, reaching 974 million yuan [42] - Xingwang Yuda reported a net profit growth of 260%, totaling 38.37 million yuan [43] - Tongyou Technology turned a profit with a net profit of 9.29 million yuan [44]

人民财讯10月20日电，山河药辅（300452）10月20日发布2025年第三季度报告，公司第三季度实现营业 收入2.26亿元，同比增长16.06%；归母净利润3952.88万元，同比增长46.99%。前三季度实现营业收入 6.97亿元，同比增长8.09%；归母净利润1.33亿元，同比增长8.28%。 ...

格隆汇10月20日丨山河药辅(300452.SZ)公布三季度报告，前三季营业收入6.97亿元，同比增长8.09%， 归属于上市公司股东的净利润1.3亿元，同比增长8.28%，归属于上市公司股东的扣除非经常性损益的净 利润1.2亿元，同比增长14.02%。 ...

Core Viewpoint - Shanhe Pharmaceutical Auxiliary (300452.SZ) reported a year-on-year increase in revenue and net profit for the first three quarters of 2025, indicating positive financial performance and growth potential [1] Financial Performance - The company's operating revenue for the first three quarters reached 697 million yuan, representing a year-on-year growth of 8.09% [1] - The net profit attributable to shareholders of the listed company was 133 million yuan, showing a year-on-year increase of 8.28% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 120 million yuan, reflecting a year-on-year growth of 14.02% [1] - Basic earnings per share stood at 0.57 yuan [1]

Group 1 - The core viewpoint of the article highlights that the company, Shanhe Pharmaceutical, reported a revenue of 226 million yuan in the third quarter, representing a year-on-year growth of 16.06% [1] - The net profit for the third quarter was 39.5288 million yuan, showing a significant year-on-year increase of 46.99% [1] - For the first three quarters, the total revenue reached 697 million yuan, which is an 8.09% increase compared to the same period last year [1] - The net profit for the first three quarters amounted to 133 million yuan, reflecting a year-on-year growth of 8.28% [1]

证券代码：300452 证券简称：山河药辅 公告编号：2025-055 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 安徽山河药用辅料股份有限公司 董 事 会 二〇二五年十月二十日 附件： 吴长虹简历 关于补选非独立董事的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担个别及连带责任。 安徽山河药用辅料股份有限公司（下称"公司"）于 2025 年 10 月 20 日召开第六届董事会第八次会议，审议通过了《关于补选公司 第六届董事会非独立董事的议案》。经公司董事会提名，第六届董事 会提名委员会审查，董事会同意提名吴长虹女士（候选人简历详见附 件）为公司第六届董事会非独立董事候选人，任职期限自股东会审议 通过之日起至公司第六届董事会届满之日止。 本次补选董事完成后，公司董事会董事的组成和人数符合《中华 人民共和国公司法》《公司章程》等有关规定，公司董事会中兼任公 司高级管理人员人数总计未超过公司董事总数的二分之一。 特此公告。 吴长虹女士：1966 出生，毕业于安徽中医药大学中药专业，本 科学历，高级讲师， ...

证券代码：300452 证券简称：山河药辅 公告编号：2025-057 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 关于使用部分暂时闲置募集资金购买的理财产品到期赎回 及继续购买理财产品的进展公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 安徽山河药用辅料股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日召开公司第六届董事会第五次会议、第六届监事会第五 次会议，审议通过了《关于使用部分闲置募集资金进行现金管理和部 分闲置自有资金进行委托理财的议案》，在不影响募集资金投资项目 正常进行及公司正常生产经营并确保资金安全的前提下，公司及子公 司使用额度不超过人民币 0.5 亿元（含本数）的闲置募集资金进行现 金管理，使用期限自股东大会审议通过之日起 12 个月，公司监事会、 保荐机构对该事项已发表明确同意意见。2024 年 5 月 13 日，公司召 开 2024 年度股东大会审议通过了上述议案。 一、到期赎回的理财产品情况 公司于 2025 年 6 月 23 日使用暂时闲置的公开发行可转换公 司债券募集资金购买了交通银行"蕴通财 ...